USPTO Examiner DARB HAMZA A - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18819040Medicament Delivery DeviceAugust 2024April 2025Allow710YesNo
18799903Method of Joining Sterile ConnectorsAugust 2024December 2024Allow410YesNo
18666217FLUIDICS CONTROL SYSTEM FOR MULTI CATHETER STACKMay 2024March 2025Allow1021NoNo
18560984SYSTEM AND METHOD FOR DETECTING FLUID TYPE IN TUBING FOR FLUID INJECTOR APPARATUSNovember 2023October 2024Allow1120NoNo
18031537A CONNECTORApril 2023August 2024Allow1620YesNo
18157184PESSARY SYSTEM AND METHOD FOR PELVIC FLOOR LIGAMENT SUPPORTJanuary 2023March 2025Allow2610YesNo
18059618Palm Activated Drug Delivery DeviceNovember 2022May 2025Allow3020YesNo
17822975METHODS AND DEVICES FOR VASCULAR ACCESSAugust 2022April 2024Abandon1930NoYes
17822006Reinforced Balloon CatheterAugust 2022August 2024Allow2420YesNo
17871460BODY CAVITY IRRIGATION AND DRAINAGE SYSTEMJuly 2022September 2024Allow2620YesNo
17868833METHOD AND DEVICE FOR THE ENHANCEMENT OF TOPICAL TREATMENTS FOR ORAL MUCOSITIS AND OTHER ORAL CONDITIONSJuly 2022November 2024Abandon2810NoNo
17869570MEDICAMENT DELIVERY DEVICES FOR ADMINISTRATION OF A MEDICAMENT WITHIN A PREFILLED SYRINGEJuly 2022May 2025Allow3320YesNo
17864528ENDOSCOPIC BENDABLE TUBE, ENDOSCOPE, AND METHOD OF MANUFACTURING ENDOSCOPIC BENDABLE TUBEJuly 2022November 2023Allow1711YesNo
17852470DICLOFENAC AND HYALURONIC ACID COMBINATION TREATMENT FOR ORAL LEUKPOPLAKIAJune 2022March 2025Abandon3220NoNo
17839197APPARATUS AND METHODS FOR ACCESSING THE LYMPHATIC SYSTEMJune 2022November 2024Allow2911NoNo
17828055PHARMACEUTICAL SYRINGE PISTONMay 2022January 2023Allow710NoNo
17729811NASAL IRRIGATION ASSEMBLY AND SYSTEMApril 2022November 2024Abandon3120NoNo
17659237VALVE FOR DILATOR AND SHEATH ASSEMBLYApril 2022May 2025Allow3740YesYes
17653352INJECTION ANALGESIA SYSTEMMarch 2022December 2024Allow3330YesNo
17636752METHOD AND APPARATUS FOR DELIVERY OF CELL THERAPIESFebruary 2022November 2024Abandon3340NoNo
17651410PESSARY SYSTEM AND METHOD FOR PELVIC FLOOR LIGAMENT SUPPORTFebruary 2022August 2022Allow610YesNo
17549672System and method for plaque serrationDecember 2021September 2022Allow920YesNo
17546092STIMULATION OF PENIS ERECTIONDecember 2021October 2024Abandon3420NoNo
17510078BENEFICIAL AGENT DISPENSEROctober 2021July 2024Abandon3320NoNo
17510068BENEFICIAL AGENT DISPENSEROctober 2021July 2024Abandon3320NoNo
17503720DIABETES MANAGEMENT SYSTEM WITH AUTOMATIC BASAL AND MANUAL BOLUS INSULIN CONTROLOctober 2021April 2024Allow3010NoNo
17498792METHOD AND DEVICE FOR THE ENHANCEMENT OF TOPICAL TREATMENTS FOR ORAL MUCOSITIS AND OTHER ORAL CONDITIONSOctober 2021March 2025Abandon4110NoNo
17494640INTRAVASCULAR DEVICEOctober 2021November 2024Allow3730YesNo
17490136SYSTEM AND METHOD FOR LAUNCHING USAGE MODE IN A MULTIMODAL SURGICAL GAS DELIVERY SYSTEMSeptember 2021February 2024Allow2830YesNo
17491390VENTRICULAR UNLOADING SYSTEMSeptember 2021September 2024Allow3530YesNo
17478546MEDICAMENT INJECTION DEVICESeptember 2021July 2024Allow3430YesNo
17464993EMBOLIZATION MICROCATHETER HEAD HAVING SLITTED PATTERNSeptember 2021January 2024Allow2810YesNo
17412063METHOD OF PRODUCING SUBSTANCES WITH SUPERSATURATED GAS, TRANSDERMAL DELIVERY DEVICE THEREOF, AND USES THEREOFAugust 2021April 2025Allow4430NoNo
17404272System For Syringe Engagement To An InjectorAugust 2021March 2022Allow710NoNo
17397912FILTER CARTRIDGE ASSEMBLIES FOR MANAGING FLUID AND HUMIDITY IN ENDOSCOPIC SURGERYAugust 2021August 2024Abandon3730YesNo
17389894SYSTEM AND METHOD FOR PLAQUE SERRATIONJuly 2021November 2021Allow410NoNo
17390091SYSTEM AND METHOD FOR PLAQUE SERRATIONJuly 2021November 2021Allow410NoNo
17388554NON-OCCLUDING BALLOON FOR CARDIOVASCULAR DRUG DELIVERYJuly 2021September 2023Allow2610NoNo
17374740CONTINUOUS ANESTHESIA NERVE CONDUCTION APPARATUS, SYSTEM AND METHOD THEREOFJuly 2021July 2024Abandon3740YesYes
17374733CONTINUOUS ANESTHESIA NERVE CONDUCTION APPARATUS, SYSTEM AND METHOD THEREOFJuly 2021April 2024Abandon3331NoYes
17372501DEVICE COMBINING POSITIONING AND INJECTION SYSTEMS FOR INJECTION WITHIN A BODY CAVITYJuly 2021January 2024Abandon3010NoNo
17366231DOSE DETECTION SYSTEM MODULE FOR A MEDICATION DELIVERY DEVICEJuly 2021August 2024Allow3830YesNo
17303833CATHETER CONSTRUCTIONJune 2021August 2023Allow2710NoNo
17333161METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERYMay 2021August 2024Allow3940YesNo
17328578BACTERIAL BIOFILM STAINING DEVICE AND METHODS OF USEMay 2021March 2025Abandon4601NoNo
17323830DRUG DELIVERY DEVICEMay 2021June 2024Allow3710NoNo
17323759MULTI-MODAL FIVE LUMEN GAS CIRCULATION SYSTEM FOR USE IN ENDOSCOPIC SURGICAL PROCEDURESMay 2021March 2024Allow3430NoNo
17318432DRUG SUPPLY DEVICEMay 2021April 2024Abandon3520NoNo
17240414Preloaded Stylet Valve CompatibilityApril 2021July 2024Allow3940NoYes
17236487Using Alternating Electric Fields to Increase Permeability of the Blood Brain BarrierApril 2021January 2025Allow4530YesYes
17231939STEERABLE EXTENDABLE DEVICESApril 2021November 2023Abandon3101NoNo
17227957CANNULA ASSEMBLYApril 2021August 2023Allow2910NoNo
17274322LOCKING MECHANISM FOR A MODULAR ORGANIZATION SYSTEMMarch 2021October 2024Allow4320YesNo
17194108INJECTION PEN WITH DIAL BACK AND LAST DOSE CONTROLMarch 2021March 2024Allow3620YesNo
17194123INJECTION PEN WITH DIAL BACK AND LAST DOSE CONTROLMarch 2021May 2024Allow3930YesNo
17173003CATHETER CONSTRUCTIONFebruary 2021August 2021Allow610YesNo
17160728KIT AND METHOD INTENDED FOR PROSTATE SURGERYJanuary 2021February 2024Allow3620NoNo
17148757NEEDLE GUIDING SYSTEMJanuary 2021March 2025Allow5041YesNo
17104685DRUG SOLUTION ADMINISTRATION METHODNovember 2020August 2023Allow3220NoNo
17099161VASCULAR ACCESS PORTNovember 2020March 2024Abandon4030NoNo
17055229ADAPTIVE TRANSDERMAL IONTOPHORETIC INTRODUCTION SYSTEM FOR BEAUTY FIELDNovember 2020June 2024Allow4320NoNo
17052743ADJUSTABLE LENGTH NEEDLE HOUSINGNovember 2020June 2024Allow4320YesNo
17082064DICLOFENAC AND HYALURONIC ACID COMBINATION TREATMENT FOR ORAL LEUKPOPLAKIAOctober 2020October 2024Abandon4810NoNo
17076158SYSTEM AND METHOD FOR MANAGING NOCTURNAL TREATMENTOctober 2020September 2023Allow3520YesNo
17073574System For Syringe Engagement To An InjectorOctober 2020May 2021Allow710YesNo
17048888A MEDICAL DEVICE FOR USE IN A NERVE BLOCK PROCEDURE THAT OBVIATES THE NEED FOR INJECTING TEST DOSES AND A METHODOctober 2020September 2024Allow4730YesNo
17072864VALVE FOR DILATOR AND SHEATH ASSEMBLYOctober 2020October 2023Allow3620YesYes
17072421VALVE FOR DILATOR AND SHEATH ASSEMBLYOctober 2020October 2023Allow3620YesYes
17045708Flow Communication Unit With Unconnected and Connected ConfigurationOctober 2020July 2024Allow4520NoNo
17063228SENSOR FOR DETECTING TISSUE INFILTRATIONOctober 2020September 2023Allow3611YesNo
17041886KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLINGSeptember 2020May 2024Abandon4410NoNo
17024514BIFURCATED HUBSeptember 2020May 2025Allow5640YesNo
17023746ENHANCED STYLET FOR DRUG DEPOT INJECTORSeptember 2020May 2023Allow3210YesNo
17003143MEDICAMENT DELIVERY DEVICEAugust 2020October 2023Allow3821NoNo
17001192TITRATION FOR MEDICAL INFUSION DEVICES AND SYSTEMSAugust 2020April 2023Allow3210NoNo
16988013CATHETER INSERTION DEVICEAugust 2020February 2024Allow4320NoNo
16983349SYSTEMS AND METHODS FOR CONTROLLING NEEDLE PENETRATIONAugust 2020May 2024Allow4530NoNo
15733439RELEASABLE SAFETY CATHETER INSERTION ASSEMBLYJuly 2020August 2022Abandon2420NoYes
16965266HUB ASSEMBLYJuly 2020August 2024Allow4930YesNo
16961928THREE-WAY DEVICE FOR ANTI-BACKFLOW INFUSION AND DOSINGJuly 2020March 2024Abandon4410NoNo
16957640PEN NEEDLE ASSEMBLY APPARATUSJune 2020November 2022Allow2910YesNo
16908556SYSTEMS AND METHODS FOR PERFORMING MEDICAL PROCEDURES INVOLVING ACCESSING THE LYMPHATIC SYSTEMJune 2020August 2023Allow3710NoNo
16902154CATHETER CONSTRUCTIONJune 2020June 2021Allow1211YesNo
16902159CATHETER CONSTRUCTIONSJune 2020November 2020Allow610YesNo
16771037IMPROVED SAFETY CATHETER NEEDLEJune 2020July 2021Allow1410NoNo
16890580METHODS AND DEVICES FOR LOCALIZING COMPOSITIONSJune 2020January 2021Allow720NoNo
16874144Closed Tip Dynamic Microvalve Protection DeviceMay 2020March 2024Allow4630NoNo
16869110Adductor Canal Block IntroducerMay 2020July 2023Allow3820YesNo
16761341Injection Device with a PreselectorMay 2020November 2022Abandon3110NoNo
16858348DISPOSABLE INTRAVENOUS (IV) SET WITH FLOW CONTROL VALVEApril 2020September 2023Allow4120YesNo
16841903Adductor Canal Block IntroducerApril 2020May 2023Abandon3710NoNo
16825386STORAGE CONTAINER, PACKAGING MEMBER, AND MEDICAL INSTRUMENT SETMarch 2020May 2023Allow3810NoNo
16808784COMBINED DRUG DELIVERY METHODS AND APPARATUSMarch 2020February 2023Allow3510YesNo
16800841DEVICES AND METHODS FOR PROVIDING FOCAL COOLING TO THE BRAIN AND SPINAL CORDFebruary 2020May 2025Abandon6061NoNo
16797598SELF-SEALING SEPTUMFebruary 2020June 2024Allow5240YesNo
16789918CABLE ARRANGERFebruary 2020January 2023Abandon3510NoNo
16637077INJECTOR DELAYED CARTRIDGE PIERCING MECHANISMFebruary 2020September 2022Allow3210NoNo
16777361MEDICAL DEVICE FLUSHING SYSTEMS AND METHODSJanuary 2020February 2024Allow4810YesNo
16634108ATTACHING/DETACHING DEVICE AND MULTI-DOSE INJECTION APPARATUSJanuary 2020April 2023Allow3910YesNo
16732882Universal Portable Artificial Kidney for Hemodialysis and Peritoneal DialysisJanuary 2020March 2023Allow3820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DARB, HAMZA A..

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
4
(57.1%)
Examiner Reversed
3
(42.9%)
Reversal Percentile
65.4%
Higher than average

What This Means

With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
50
Allowed After Appeal Filing
17
(34.0%)
Not Allowed After Appeal Filing
33
(66.0%)
Filing Benefit Percentile
53.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 34.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner DARB, HAMZA A. - Prosecution Strategy Guide

Executive Summary

Examiner DARB, HAMZA A. works in Art Unit 3783 and has examined 335 patent applications in our dataset. With an allowance rate of 76.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner DARB, HAMZA A.'s allowance rate of 76.1% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by DARB, HAMZA A. receive 2.67 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DARB, HAMZA A. is 38 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +35.4% benefit to allowance rate for applications examined by DARB, HAMZA A.. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.6% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.1% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 127.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 83% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.5% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 57.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 36.9% are granted (fully or in part). This grant rate is in the 33% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 43% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.